Brolucizumab (also known as RTH258) is a humanized single-chain antibody fragment that inhibits all isoforms of VEGF-A with a molecular weight of 26 kDa.
“On a molar basis, 6 mg of brolucizumab equals approximately 12 times the 2.0-mg dose of aflibercept and 22 times the 0.5-mg dose of ranibizumab,” t
“These attributes may confer potential advantages in the treatment of neovascular AMD. A small molecular weight and high drug concentration gradient between the vitreous and retina may support drug distribution into the retina.
Assuming comparable half-life, higher molar doses of drug may be cleared more slowly from the eye, thus prolonging duration of action,” they explained.